乳腺癌中雌激素受体α表达水平调节的分子机制

doi:10.3724/SP.J.1005.2010.00191

遗传 ›› 2010, Vol. 32 ›› Issue (3): 191-197.doi: 10.3724/SP.J.1005.2010.00191

乳腺癌中雌激素受体α表达水平调节的分子机制

程龙,黄翠芬,叶棋浓

军事医学科学院生物工程研究所, 北京 100850

收稿日期:2009-11-24 修回日期:2010-02-04 出版日期:2010-03-20 发布日期:2010-03-15
通讯作者: 叶棋浓 E-mail:yeqn66@yahoo.com
基金资助:
国家自然科学基金项目(编号：30530320, 30625035)资助

Molecular mechanisms of regulation of estrogen receptor a expression level in breast cancer

CHENG Long,HUANG Cui-Fen,YE Qi-Nong

Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100850, China

Received:2009-11-24 Revised:2010-02-04 Online:2010-03-20 Published:2010-03-15
Contact: YE Qi-Nong E-mail:yeqn66@yahoo.com

摘要/Abstract

摘要：

雌激素受体α(ERα)在乳腺癌的发生发展中扮演重要角色, 因而ERα成为乳腺癌治疗的分子靶标。ERα的表达水平在乳腺癌患者中差异较大, 即使同一患者, 在乳腺癌的不同阶段也可能有很大的差别。乳腺癌内分泌治疗的疗效以及预后都与ERα表达水平密切相关。影响ERα表达水平的分子机制复杂, 众多调节分子在染色质、转录、转录后、翻译和翻译后等水平参与ERα表达水平的调节。在染色质和转录水平, 许多分子通过直接或间接地与ERa启动子的相互作用改变ERα的转录; 在转录后/翻译水平, 一些microRNA通过诱导ERα mRNA的降解和/或抑制其翻译降低ERα的水平; 在翻译后水平, 许多分子通过泛素-蛋白酶体途径调节ERα蛋白水平。文章从不同水平, 对这些调节分子的调节机制进行简要综述。

关键词: 乳腺癌, 基因表达调控, 雌激素受体α

Abstract:

Estrogen receptor α(ERα) plays an important role in breast cancer development and progression and thus becomes a useful molecular target for breast cancer therapy. ERα is differentially expressed in breast cancer patients. Moreover, ERα expression levels may change at different stages of breast cancer even for the same patient. ERα expression is closely associated with the effect of endocrine therapy and prognosis. The mechanisms underlying ERα expression are complicated, because ERα expression is regulated at different levels, including chromatin, transcriptional, post- transcriptional, translational, and post-translational levels. Many proteins modulate the transcription of ERα gene at the chromatin and transcriptional levels through direct or indirect interaction with the ERα promoter. Some microRNAs decrease ERα levels possibly by induction of the degradation of ERα mRNA and/or repression of the mRNA translation. At the post-translational level, many proteins regulate ERα protein levels through ubiquitin-proteosome pathway. This review focuses on molecular mechanisms of regulation of ERa expression at different levels.

Key words: breast cancer, gene expression regulation, estrogen receptor α

程龙，黄翠芬，叶棋浓. 乳腺癌中雌激素受体α表达水平调节的分子机制[J]. 遗传, 2010, 32(3): 191-197.

参考文献

[1] Beato M. Gene regulation by steroid hormones. Cell, 1989, 56(3): 335-344.

[2] Menasce LP, White GR, Harrison CJ, Boyle JM. Local-ization of the estrogen receptor locus (ESR) to chromo-some 6q25.1 by FISH and a simple post-FISH banding technique. Genomics, 1993, 17(1): 263-265.

[3] Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C, Coombes RC. Estrogen and proges-terone receptors in the normal female breast. Cancer Res, 1991, 51(7): 1817-1822.

[4] Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation-specific polymerase chain reac-tion. Cancer Res, 1998, 58(12): 2515-2519.

[5] Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res, 1994, 54(10): 2552-2555.

[6] Zhao L, Wang L, Jin F, Ma W, Ren J, Wen X, He M, Sun M, Tang H, Wei M. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a fre-quent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat, 2009, 117(2): 253-259.

[7] Ferguson AT, Lapidus RG, Davidson NE. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene, 1998, 17(5): 577-583.

[8] Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. Transcriptional ac-tivation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res, 2000, 60(24): 6890-6894.

[9] Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen recep-tor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther, 2003, 2(5): 552-556.

[10] Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estro-gen receptor alpha. Int J Cancer, 2003, 107(3): 353-358.

[11] Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res, 2009, 15(9): 3163-3171.

[12] Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a com-plex at replication foci. Nat Genet, 2000, 25(3): 269-277.

[13] El-Osta A, Wolffe AP. DNA methylation and histone deace-tylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr, 2000, 9(1-2): 63-75.

[14] Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA me-thylation to histone methylation. J Biol Chem, 2003, 278(6): 4035-4040.

[15] Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol, 2005, 19(7): 1740-1751.

[16] Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen re-ceptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat, 2003, 81(3): 177-186.

[17] Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, di Gh, Shen ZZ, Shao ZM. ER alpha negative breast cancer cells re-store response to endocrine therapy by combination treat-ment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol, 2008, 134(8): 883-890.

[18] Keaveney M, Klug J, Dawson MT, Nestor PV, Neilan JG, Forde RC, Gannon F. Evidence for a previously unidenti-fied upstream exon in the human oestrogen receptor gene. J Mol Endocrinol, 1991, 6(1): 111-115.

[19] Piva R, Bianchi N, Aguiari GL, Gambari R, Del SL. Se-quencing of an RNA transcript of the human estrogen re-ceptor gene: evidence for a new transcriptional event. J Steroid Biochem Mol Biol, 1993, 46(5): 531-538.

[20] Grandien KF, Berkenstam A, Nilsson S, Gustafsson JA. Localization of DNase I hypersensitive sites in the human oestrogen receptor gene correlates with the transcriptional activity of two differentially used promoters. J Mol Endocrinol, 1993, 10(3): 269-277.

[21] Hayashi S, Imai K, Suga K, Kurihara T, Higashi Y, Na-kachi K. Two promoters in expression of estrogen receptor messenger RNA in human breast cancer. Carcinogenesis, 1997, 18(3): 459-464.

[22] Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential expression of the human es-trogen receptor in breast cancers. Mol Cell Biol, 1997, 17(3): 1274-1280.

[23] Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol, 2004, 24(19): 8681-8690.

[24] Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, Yao KM, Lam EW. The Forkhead box M1 protein regulates the transcription of the estrogen re-ceptor alpha in breast cancer cells. J Biol Chem, 2006, 281(35): 25167-25176.

[25] Deconinck EC, Mcpherson LA, Weigel RJ. Transcrip-tional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol, 1995, 15(4): 2191-2196.

[26] Mcpherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA, 1997, 94(9): 4342-4347.

[27] Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res, 2007, 67(18): 8439-8443.

[28] Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ. Interaction of TFAP2C with the estrogen re-ceptor-alpha promoter is controlled by chromatin structure. Clin Cancer Res, 2009, 15(11): 3672-3679.

[29] Tanimoto K, Eguchi H, Yoshida T, Hajiro-Nakanishi K, Hayashi S. Regulation of estrogen receptor alpha gene mediated by promoter B responsible for its enhanced ex-pressionin human breast cancer. Nucleic Acids Res, 1999, 27(3): 903-909.

[30] Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor- alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol, 2004, 180(3): 497-504.

[31] Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R. Human X-box binding protein-1 confers both estrogen in-dependence and antiestrogen resistance in breast cancer cell lines. FASEB J, 2007, 21(14): 4013-4027.

[32] Adams BD, Furneaux H, White BA. The mi-cro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol, 2007, 21(5): 1132-1147.

[33] Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen recep-tor alpha-positive human breast cancer. Cancer Res, 2008, 68(13): 5004-5008.

[34] Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates es-trogen receptor alpha and is associated with t moxifen resistance in breast cancer. J Biol Chem, 2008, 283(45): 31079-31086.

[35] Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R, Safe S. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol, 2003, 23(6): 1843-1855.

[36] Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA, 1999, 96(5): 1858-1862.

[37] Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell, 2003, 11(3): 695-707.

[38] Luo M, Koh M, Feng J, Wu Q, Melamed P. Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation. Mol Cell Biol, 2005, 25(16): 7386-7398.

[39] Chu I, Arnaout A, Loiseau S, Sun J, Seth A, Mcmahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest, 2007, 117(8): 2205-2215.

[40] Shao W, Keeton EK, Mcdonnell DP, Brown M. Coactiva-tor AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA, 2004, 101(32): 11599-11604.

[41] Nakajima A, Maruyama S, Bohgaki M, Miyajima N, Tsu-kiyama T, Sakuragi N, Hatakeyama S. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun, 2007, 357(1): 245-251.

[42] Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Mu-rayama A, Tanaka K, Baba T, Kato S, Yanagisawa J. Ligand- dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J, 2004, 23(24): 4813-4823.

[43] Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavailles V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res, 2007, 67(11): 5513-5521.

[44] Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol, 2007, 21(10): 2427-2439.

[45] Park S, Song J, Joe CO, Shin I. Akt stabilizes estrogen receptor alpha with the concomitant reduction in its tran-scriptional activity. Cell Signal, 2008, 20(7): 1368-1374.

[46] Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell, 2006, 21(2): 295-305.

[47] Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is in-volved in ligand-dependent degradation of estrogen re-ceptor {alpha} by the proteasome. Mol Cell Biol, 2005, 25(11): 4349-4358.

[48] Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA. Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol Cell Biol, 2003, 23(17): 5979-5988.

[49] Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiq-uitin ligase. Proc Natl Acad Sci USA, 2007, 104(14): 5794-5799.

[50] Li L, Li Z, Howley PM, Sacks DB. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J Biol Chem, 2006, 281(4): 1978-1985.

[51] Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiprolif-erative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol, 2003, 17(3): 356-365.

[52] Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell, 2008, 30(3): 336-347.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

乳腺癌中雌激素受体α表达水平调节的分子机制

Molecular mechanisms of regulation of estrogen receptor a expression level in breast cancer

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	禹奇超,宋彬,邹轩轩,王岭,刘德权,李波,马昆. 乳腺癌癌旁组织特异性表达基因分析[J]. 遗传, 2019, 41(7): 625-633.
[2]	余同露,蔡栋梁,朱根凤,叶晓娟,闵太善,陈红岩,卢大儒,陈浩明. CSN4基因干扰对乳腺癌MDA-MB-231细胞增殖和凋亡的影响[J]. 遗传, 2019, 41(4): 318-326.
[3]	宁椿游,何梦楠,唐茜子,朱庆,李明洲,李地艳. 基于Hi-C技术哺乳动物三维基因组研究进展[J]. 遗传, 2019, 41(3): 215-233.
[4]	姚传波, 周鑫, 陈策实, 雷群英. Hippo信号通路在乳腺癌中的调控机制及作用[J]. 遗传, 2017, 39(7): 617-629.
[5]	施剑,李艳明,方向东. 长链非编码RNA通过细胞核高级结构调控真核基因表达及其临床意义[J]. 遗传, 2017, 39(3): 189-199.
[6]	路畅, 黄银花. 动物长链非编码RNA研究进展[J]. 遗传, 2017, 39(11): 1054-1065.
[7]	李泰明, 蓝文俊, 黄灿, 张春, 刘晓玫. 近红外荧光蛋白标记乳腺癌细胞外泌体的构建及鉴定[J]. 遗传, 2016, 38(5): 427-435.
[8]	翟亚男, 许泉, 郭亚, 吴强. 原钙粘蛋白基因簇调控区域中成簇的CTCF结合位点分析[J]. 遗传, 2016, 38(4): 323-336.
[9]	黄小庆,李丹丹,吴娟. 植物长链非编码RNA研究进展[J]. 遗传, 2015, 37(4): 344-359.
[10]	施子晗, 李泽琴, 张根发. 植物组蛋白赖氨酸化修饰参与基因表达调控的机理[J]. 遗传, 2014, 36(3): 208-219.
[11]	张韬杨足君. 植物基因组DNase I超敏感位点的研究进展[J]. 遗传, 2013, 35(7): 867-874.
[12]	夏天，肖丙秀，郭俊明. 长链非编码RNA的作用机制及其研究方法[J]. 遗传, 2013, 35(3): 269-280.
[13]	秦丹徐存拴. 非编码DNA序列的功能及其鉴定[J]. 遗传, 2013, 35(11): 1253-1264.
[14]	李泽琴，李静晓，张根发. 植物抗坏血酸过氧化物酶的表达调控以及对非生物胁迫的耐受作用[J]. 遗传, 2013, 35(1): 45-54.
[15]	吴新刚，彭姝彬，黄谦. 乳腺癌耐药蛋白基因的转录调控机制[J]. 遗传, 2012, 34(12): 1529-1536.